...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Why now?

ryau - Probably the biggest reason is that they can't get the number of shares they want OTC. Also, the OTC is a mostly unregulated wild west show that many of those type of investors aren't interested in. Also there might be warrants attached to a PP that improves the price some. Maybe other reasons I haven't thought of also.

Share
New Message
Please login to post a reply